EGFR and glioblastoma: These cells have been modified to target neuroblastoma using a GD2 (disialoganglioside)-specific CAR (Esser et al., 2012) and to target glioblastoma using either an ErbB2 (origin in the ERB-B gene responsible for avian erythroblastosis virus)-CAR (Zhang et al., 2016) or an EGFR-CAR (Han et al., 2015).